Generic Name
Paclitaxel
Brand Names
Paclitaxel Protein-Bound, Abraxane
FDA approval date: March 01, 2004
Classification: Microtubule Inhibitor
Form: Injection
What is Paclitaxel Protein-Bound (Paclitaxel)?
Paclitaxel protein-bound particles for injectable suspension is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment